Bioniq Secures $15M for Hyper-Personalized Supplements
The U.K.-based supplement brand uses AI and blood biomarker data to recommend highly personalized blends
The desire for hyper-personalization in all aspects of health and wellness has reached supplements.
Bioniq, which offers artificial intelligence (AI)-powered personalized supplements based on blood biomarker data, has raised $15 million in an oversubscribed Series B funding round led by HV Capital and Unbound.
The London-based brand says it will use the capital for product development and growth in the United States and the Middle East and a corporate platform for medical, wellness and athletic institutions.
Earlier this year, Bioniq announced a partnership with Al Borg Diagnostics, a diagnostic health services provider in Saudi Arabia.
Founded in 2019 in London, Bioniq says its personalized approach has led to sizable growth in the last twelve months —particularly in the U.S. — which is over 50% of its customer base. Certain other regions have grown over 500% in the last two quarters, according to Bioniq.
“We’ve entered a new era in nutritional supplementation over the last six years, where it’s become clear that one-size-fits-all solutions are simply inefficient,” said Bioniq co-founder and CEO Vadim Fedotov. “Everyone’s health journey is unique and fluid. Customers need advanced, adaptable products that provide evolving support for personal health goals.”
The company has amassed an extensive proprietary biochemical database using blood test data from its customers. Its patent-pending algorithm considers a user’s height, weight, age, lifestyle and health goals to identify micronutrient imbalances and develop a personalized supplement blend.
The health tech startup offers consumers two options: Pro and Go.
Bioniq Pro is comprehensive and highly personalized, incorporating blood biomarker data into its AI-powered algorithm. Users can either upload existing bloodwork to receive recommendations or schedule a blood test through a Bioniq partner lab. The data is analyzed for nutrient status and imbalances, providing users with a specially-made daily supplement formula. Users can also discuss their needs with a registered dietitian.
The Go option is designed to be accessible for wellness-seekers and is based on a questionnaire. Bioniq’s AI algorithm still plays a role with the Go route, recommending supplement blends based on individual responses and previous users’ blood biomarker data.
Instead of pills or capsules, Bioniq’s personalized supplements come in the form of granules for better absorption and are shipped globally with a subscription model.
“Bioniq’s exceptional growth is a testament to its innovative approach for high-quality personalized health solutions that professional athletes across the world rely on,” HV Capital general partner David Kuczek said. “With sales from across 60 countries, with the majority coming from North America, the most important market for health solutions globally, Bioniq is well-positioned to continue its trajectory of rapid expansion.”
